Approval by the Ethics Committee of the University Hospital of Cologne (No. 09-182) was obtained prior to inclusion. The study was conducted in accordance with the Declaration of Helsinki. From ...

Please provide your email address to receive an email when new articles are posted on . BARCELONA, Spain — A post hoc analysis of PULSAR trial data showed sustained fluid control at 2 years with fewer ...

Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study. This is an ASCO Meeting Abstract from the 2021 Gastrointestinal Cancers ...

Amid desperate efforts to find a treatment for the neurodegenerative disease Alzheimer’s, the aducanumab saga continues, as a US Food and Drug Administration panel will determine whether a post-hoc ...

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...

A newer tool used to assess cardiovascular disease risk comes with both answers…and some questions. “These results were not surprising to us,” investigators Adam Bress, PharmD, MS, and Catherine ...

Treatment response monitoring in chronic phase CML (CP-CML) patients receiving tyrosine kinase inhibitor (TKI) therapy in US Oncology network. This is an ASCO Meeting Abstract from the 2013 ASCO ...

Please provide your email address to receive an email when new articles are posted on . At day 84, 55.3% of patients achieved a reduction in eye dryness of 60% or more. Patients with quick, dramatic ...

A lower-than-recommended dose of edoxaban (Savaysa; Daiichi Sankyo) lessens bleeding without compromising protection against ischemic events in elderly patients with atrial fibrillation (AF), a post ...